Concepts (347)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cognition | 49 | 2023 | 1250 | 7.960 |
Why?
|
| Brain | 40 | 2023 | 1569 | 4.960 |
Why?
|
| Aging | 36 | 2023 | 1483 | 4.620 |
Why?
|
| White Matter | 11 | 2022 | 131 | 4.610 |
Why?
|
| Cognitive Dysfunction | 32 | 2023 | 990 | 4.040 |
Why?
|
| Aged | 118 | 2023 | 8732 | 3.800 |
Why?
|
| Alzheimer Disease | 30 | 2023 | 2036 | 3.540 |
Why?
|
| Neuropsychological Tests | 61 | 2023 | 1150 | 3.540 |
Why?
|
| Cardiovascular Diseases | 13 | 2023 | 307 | 3.360 |
Why?
|
| Magnetic Resonance Imaging | 38 | 2023 | 1059 | 2.890 |
Why?
|
| Cognition Disorders | 19 | 2020 | 957 | 2.850 |
Why?
|
| Diffusion Tensor Imaging | 12 | 2023 | 57 | 2.700 |
Why?
|
| Humans | 147 | 2023 | 25967 | 2.680 |
Why?
|
| Female | 103 | 2023 | 14734 | 2.570 |
Why?
|
| Male | 100 | 2023 | 14277 | 2.530 |
Why?
|
| Hypertension | 7 | 2022 | 181 | 2.390 |
Why?
|
| Depression | 8 | 2020 | 412 | 2.230 |
Why?
|
| Executive Function | 21 | 2023 | 102 | 2.130 |
Why?
|
| Middle Aged | 72 | 2023 | 8772 | 2.110 |
Why?
|
| Blood Pressure | 8 | 2022 | 184 | 1.940 |
Why?
|
| Aged, 80 and over | 55 | 2023 | 4641 | 1.930 |
Why?
|
| Dementia | 16 | 2023 | 524 | 1.780 |
Why?
|
| Verbal Learning | 11 | 2021 | 29 | 1.770 |
Why?
|
| Memory Disorders | 7 | 2018 | 154 | 1.710 |
Why?
|
| Diet, Mediterranean | 5 | 2023 | 82 | 1.700 |
Why?
|
| Acculturation | 3 | 2023 | 30 | 1.690 |
Why?
|
| Memory, Short-Term | 11 | 2023 | 91 | 1.670 |
Why?
|
| Connectome | 5 | 2021 | 11 | 1.650 |
Why?
|
| Risk Factors | 26 | 2023 | 2237 | 1.600 |
Why?
|
| Gray Matter | 5 | 2023 | 50 | 1.520 |
Why?
|
| Prefrontal Cortex | 7 | 2016 | 128 | 1.510 |
Why?
|
| Neuroimaging | 10 | 2023 | 120 | 1.460 |
Why?
|
| Health Literacy | 3 | 2023 | 106 | 1.410 |
Why?
|
| Cerebrovascular Disorders | 4 | 2021 | 127 | 1.350 |
Why?
|
| Residence Characteristics | 4 | 2021 | 205 | 1.290 |
Why?
|
| Decision Making | 6 | 2023 | 216 | 1.250 |
Why?
|
| Arteriolosclerosis | 3 | 2023 | 74 | 1.150 |
Why?
|
| Brain Mapping | 10 | 2021 | 145 | 1.150 |
Why?
|
| Public Health | 6 | 2021 | 64 | 1.140 |
Why?
|
| United States | 18 | 2021 | 1989 | 1.070 |
Why?
|
| Mental Status and Dementia Tests | 4 | 2021 | 53 | 1.060 |
Why?
|
| Cohort Studies | 19 | 2023 | 1806 | 1.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 158 | 1.020 |
Why?
|
| Depressive Disorder | 5 | 2017 | 172 | 1.010 |
Why?
|
| Depressive Disorder, Major | 9 | 2018 | 93 | 0.990 |
Why?
|
| Nerve Fibers, Myelinated | 5 | 2013 | 25 | 0.990 |
Why?
|
| Memory | 10 | 2021 | 285 | 0.980 |
Why?
|
| Tryptophan | 5 | 2014 | 10 | 0.980 |
Why?
|
| Apolipoproteins E | 4 | 2023 | 235 | 0.960 |
Why?
|
| Exercise | 7 | 2022 | 434 | 0.930 |
Why?
|
| Stroke | 5 | 2023 | 259 | 0.930 |
Why?
|
| Cross-Sectional Studies | 14 | 2023 | 851 | 0.930 |
Why?
|
| Cognitive Aging | 3 | 2020 | 77 | 0.920 |
Why?
|
| Hippocampus | 9 | 2022 | 266 | 0.890 |
Why?
|
| Psychomotor Performance | 9 | 2020 | 179 | 0.880 |
Why?
|
| Educational Status | 5 | 2023 | 282 | 0.880 |
Why?
|
| Diabetes Mellitus | 3 | 2020 | 121 | 0.860 |
Why?
|
| Pattern Recognition, Visual | 2 | 2019 | 16 | 0.860 |
Why?
|
| Linear Models | 6 | 2020 | 240 | 0.830 |
Why?
|
| Spatial Processing | 2 | 2021 | 6 | 0.820 |
Why?
|
| Adult | 28 | 2023 | 7662 | 0.820 |
Why?
|
| Mental Recall | 7 | 2020 | 61 | 0.800 |
Why?
|
| Income | 3 | 2021 | 77 | 0.790 |
Why?
|
| Genotype | 5 | 2020 | 339 | 0.780 |
Why?
|
| Social Participation | 1 | 2022 | 12 | 0.770 |
Why?
|
| Blood Glucose | 2 | 2022 | 102 | 0.760 |
Why?
|
| Crime Victims | 1 | 2022 | 26 | 0.760 |
Why?
|
| Leukoaraiosis | 3 | 2012 | 8 | 0.760 |
Why?
|
| Analysis of Variance | 10 | 2017 | 252 | 0.740 |
Why?
|
| Clinical Protocols | 1 | 2022 | 57 | 0.740 |
Why?
|
| Anisotropy | 5 | 2023 | 42 | 0.730 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2018 | 160 | 0.720 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 39 | 0.720 |
Why?
|
| Longitudinal Studies | 13 | 2023 | 1333 | 0.720 |
Why?
|
| Cerebral Cortex | 4 | 2021 | 151 | 0.710 |
Why?
|
| Psychology | 1 | 2021 | 21 | 0.710 |
Why?
|
| Optimism | 1 | 2021 | 1 | 0.700 |
Why?
|
| Family Relations | 1 | 2021 | 12 | 0.700 |
Why?
|
| Antihypertensive Agents | 2 | 2020 | 46 | 0.690 |
Why?
|
| Social Segregation | 1 | 2020 | 7 | 0.680 |
Why?
|
| Social Environment | 1 | 2021 | 77 | 0.680 |
Why?
|
| Racism | 1 | 2021 | 29 | 0.680 |
Why?
|
| Dementia, Vascular | 5 | 2020 | 45 | 0.670 |
Why?
|
| Loneliness | 1 | 2021 | 54 | 0.670 |
Why?
|
| Cholesterol | 2 | 2019 | 59 | 0.660 |
Why?
|
| Social Capital | 1 | 2020 | 2 | 0.660 |
Why?
|
| Dyslipidemias | 1 | 2019 | 16 | 0.630 |
Why?
|
| Triglycerides | 1 | 2019 | 56 | 0.630 |
Why?
|
| Social Support | 1 | 2021 | 190 | 0.630 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 38 | 0.630 |
Why?
|
| Life Style | 1 | 2021 | 177 | 0.630 |
Why?
|
| Hyperinsulinism | 1 | 2019 | 4 | 0.620 |
Why?
|
| Prospective Studies | 13 | 2022 | 1701 | 0.610 |
Why?
|
| Mental Processes | 1 | 2019 | 15 | 0.610 |
Why?
|
| Cultural Diversity | 1 | 2019 | 20 | 0.610 |
Why?
|
| Stress, Psychological | 1 | 2021 | 227 | 0.600 |
Why?
|
| Community Health Services | 1 | 2019 | 32 | 0.600 |
Why?
|
| Independent Living | 6 | 2022 | 283 | 0.590 |
Why?
|
| Insulin Resistance | 1 | 2019 | 50 | 0.590 |
Why?
|
| Neural Pathways | 9 | 2018 | 61 | 0.590 |
Why?
|
| Multilingualism | 1 | 2019 | 21 | 0.590 |
Why?
|
| Phenotype | 2 | 2019 | 290 | 0.590 |
Why?
|
| Kidney | 1 | 2019 | 147 | 0.590 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2023 | 159 | 0.570 |
Why?
|
| Psychological Trauma | 1 | 2017 | 2 | 0.550 |
Why?
|
| Affect | 3 | 2013 | 59 | 0.530 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 366 | 0.520 |
Why?
|
| Wounds and Injuries | 1 | 2017 | 44 | 0.520 |
Why?
|
| Serotonin | 4 | 2014 | 23 | 0.510 |
Why?
|
| Individuality | 1 | 2016 | 18 | 0.500 |
Why?
|
| Metabolic Diseases | 1 | 2015 | 7 | 0.460 |
Why?
|
| Thinking | 1 | 2014 | 14 | 0.450 |
Why?
|
| Psychomotor Disorders | 1 | 2014 | 10 | 0.450 |
Why?
|
| Verbal Behavior | 5 | 2009 | 15 | 0.450 |
Why?
|
| Obesity | 4 | 2023 | 297 | 0.440 |
Why?
|
| Sex Factors | 6 | 2020 | 454 | 0.440 |
Why?
|
| Surveys and Questionnaires | 10 | 2021 | 1107 | 0.430 |
Why?
|
| Age Factors | 8 | 2020 | 757 | 0.430 |
Why?
|
| Frontal Lobe | 5 | 2018 | 78 | 0.420 |
Why?
|
| Vascular Diseases | 2 | 2013 | 40 | 0.420 |
Why?
|
| Memory, Episodic | 3 | 2018 | 110 | 0.410 |
Why?
|
| Alleles | 5 | 2023 | 204 | 0.410 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2012 | 31 | 0.390 |
Why?
|
| Health Surveys | 4 | 2021 | 87 | 0.390 |
Why?
|
| Attention | 6 | 2023 | 106 | 0.390 |
Why?
|
| Models, Statistical | 3 | 2021 | 126 | 0.380 |
Why?
|
| Galvanic Skin Response | 1 | 2011 | 7 | 0.370 |
Why?
|
| Gambling | 1 | 2011 | 8 | 0.370 |
Why?
|
| Case-Control Studies | 9 | 2023 | 571 | 0.370 |
Why?
|
| Models, Psychological | 1 | 2011 | 67 | 0.360 |
Why?
|
| Dancing | 2 | 2021 | 14 | 0.360 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2023 | 125 | 0.360 |
Why?
|
| Biomarkers | 4 | 2021 | 544 | 0.360 |
Why?
|
| Down Syndrome | 1 | 2011 | 10 | 0.360 |
Why?
|
| Brain Chemistry | 1 | 2011 | 42 | 0.350 |
Why?
|
| Crime | 2 | 2021 | 7 | 0.340 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2016 | 193 | 0.330 |
Why?
|
| Basal Ganglia Cerebrovascular Disease | 1 | 2010 | 3 | 0.330 |
Why?
|
| Sex Characteristics | 2 | 2022 | 113 | 0.330 |
Why?
|
| Chicago | 3 | 2021 | 898 | 0.320 |
Why?
|
| Reaction Time | 6 | 2023 | 91 | 0.320 |
Why?
|
| Neural Inhibition | 2 | 2014 | 8 | 0.310 |
Why?
|
| Apolipoprotein E4 | 3 | 2020 | 251 | 0.300 |
Why?
|
| Psychiatric Status Rating Scales | 7 | 2017 | 296 | 0.290 |
Why?
|
| Myelin Sheath | 2 | 2021 | 26 | 0.280 |
Why?
|
| Amnesia | 5 | 2020 | 21 | 0.270 |
Why?
|
| Learning | 2 | 2018 | 68 | 0.270 |
Why?
|
| Self Report | 3 | 2023 | 217 | 0.270 |
Why?
|
| Hospitalization | 2 | 2019 | 301 | 0.260 |
Why?
|
| Visual Perception | 2 | 2020 | 28 | 0.260 |
Why?
|
| Young Adult | 7 | 2021 | 1941 | 0.260 |
Why?
|
| Principal Component Analysis | 3 | 2021 | 22 | 0.260 |
Why?
|
| Language | 3 | 2021 | 63 | 0.260 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 649 | 0.260 |
Why?
|
| Nerve Net | 5 | 2018 | 38 | 0.250 |
Why?
|
| Prevalence | 4 | 2021 | 433 | 0.250 |
Why?
|
| Pilot Projects | 3 | 2022 | 390 | 0.250 |
Why?
|
| DNA-Binding Proteins | 3 | 2023 | 268 | 0.240 |
Why?
|
| Problem Solving | 2 | 2009 | 39 | 0.230 |
Why?
|
| Severity of Illness Index | 5 | 2017 | 868 | 0.220 |
Why?
|
| Discrimination Learning | 1 | 2004 | 1 | 0.220 |
Why?
|
| Color Perception | 1 | 2004 | 5 | 0.220 |
Why?
|
| Temporal Lobe | 3 | 2018 | 87 | 0.220 |
Why?
|
| Models, Neurological | 3 | 2018 | 24 | 0.220 |
Why?
|
| Arousal | 1 | 2004 | 49 | 0.220 |
Why?
|
| Time Factors | 2 | 2019 | 1391 | 0.210 |
Why?
|
| Autistic Disorder | 2 | 2014 | 38 | 0.200 |
Why?
|
| Postmenopause | 1 | 2023 | 57 | 0.200 |
Why?
|
| Adolescent | 6 | 2021 | 2099 | 0.200 |
Why?
|
| Research Design | 2 | 2021 | 183 | 0.200 |
Why?
|
| Intelligence Tests | 2 | 2015 | 15 | 0.200 |
Why?
|
| HIV Infections | 2 | 2021 | 434 | 0.190 |
Why?
|
| Fraud | 1 | 2022 | 21 | 0.190 |
Why?
|
| Psychometrics | 2 | 2021 | 210 | 0.190 |
Why?
|
| Atherosclerosis | 1 | 2023 | 52 | 0.190 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 473 | 0.190 |
Why?
|
| Socioeconomic Factors | 2 | 2021 | 294 | 0.190 |
Why?
|
| Geriatric Assessment | 3 | 2017 | 201 | 0.190 |
Why?
|
| Regression Analysis | 5 | 2018 | 251 | 0.190 |
Why?
|
| Awareness | 1 | 2002 | 42 | 0.180 |
Why?
|
| Facial Expression | 2 | 2012 | 8 | 0.180 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2023 | 114 | 0.180 |
Why?
|
| Data Interpretation, Statistical | 3 | 2022 | 76 | 0.180 |
Why?
|
| Genome-Wide Association Study | 2 | 2020 | 268 | 0.180 |
Why?
|
| Social Networking | 1 | 2021 | 9 | 0.180 |
Why?
|
| Emotions | 2 | 2012 | 72 | 0.180 |
Why?
|
| Social Identification | 1 | 2021 | 7 | 0.180 |
Why?
|
| Treatment Outcome | 2 | 2022 | 3399 | 0.170 |
Why?
|
| Accelerometry | 2 | 2021 | 87 | 0.170 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2021 | 13 | 0.170 |
Why?
|
| Southeastern United States | 1 | 2020 | 14 | 0.170 |
Why?
|
| Midwestern United States | 1 | 2020 | 48 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 273 | 0.170 |
Why?
|
| Organ Size | 3 | 2023 | 94 | 0.170 |
Why?
|
| Mental Status Schedule | 3 | 2011 | 89 | 0.170 |
Why?
|
| Wechsler Scales | 3 | 2006 | 11 | 0.170 |
Why?
|
| Acute Disease | 2 | 2012 | 175 | 0.160 |
Why?
|
| Space Perception | 1 | 2020 | 22 | 0.160 |
Why?
|
| Judgment | 1 | 2019 | 6 | 0.160 |
Why?
|
| Disabled Persons | 1 | 2021 | 107 | 0.160 |
Why?
|
| Cholesterol, HDL | 1 | 2019 | 26 | 0.160 |
Why?
|
| Pandemics | 1 | 2021 | 211 | 0.160 |
Why?
|
| Cholesterol, LDL | 1 | 2019 | 29 | 0.160 |
Why?
|
| Patient Selection | 1 | 2021 | 190 | 0.160 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 326 | 0.160 |
Why?
|
| Interpersonal Relations | 1 | 2020 | 98 | 0.150 |
Why?
|
| Hypercholesterolemia | 1 | 2019 | 22 | 0.150 |
Why?
|
| Atrophy | 2 | 2016 | 83 | 0.150 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 1757 | 0.150 |
Why?
|
| Financing, Personal | 1 | 2018 | 22 | 0.150 |
Why?
|
| Emergencies | 1 | 2019 | 30 | 0.150 |
Why?
|
| Energy Intake | 1 | 2019 | 77 | 0.150 |
Why?
|
| Cognitive Reserve | 1 | 2019 | 39 | 0.150 |
Why?
|
| Genetic Variation | 1 | 2018 | 93 | 0.150 |
Why?
|
| Heterozygote | 1 | 2018 | 98 | 0.140 |
Why?
|
| Double-Blind Method | 3 | 2014 | 393 | 0.140 |
Why?
|
| Healthy Aging | 1 | 2017 | 14 | 0.130 |
Why?
|
| Parkinson Disease | 2 | 2020 | 640 | 0.130 |
Why?
|
| Healthy Lifestyle | 1 | 2017 | 41 | 0.130 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2016 | 15 | 0.130 |
Why?
|
| Phobia, Social | 1 | 2016 | 13 | 0.130 |
Why?
|
| Motor Skills | 1 | 2017 | 45 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 466 | 0.130 |
Why?
|
| Self-Assessment | 2 | 2020 | 23 | 0.130 |
Why?
|
| Neurodegenerative Diseases | 1 | 2018 | 123 | 0.130 |
Why?
|
| Prognosis | 1 | 2019 | 784 | 0.130 |
Why?
|
| Gyrus Cinguli | 2 | 2016 | 14 | 0.130 |
Why?
|
| Bipolar Disorder | 1 | 2016 | 102 | 0.120 |
Why?
|
| Anxiety Disorders | 1 | 2017 | 169 | 0.120 |
Why?
|
| Urban Population | 1 | 2017 | 149 | 0.120 |
Why?
|
| Cytokines | 1 | 2017 | 225 | 0.120 |
Why?
|
| Inflammation | 3 | 2023 | 267 | 0.120 |
Why?
|
| Cerebrovascular Circulation | 2 | 2014 | 31 | 0.110 |
Why?
|
| Macromolecular Substances | 1 | 2014 | 6 | 0.110 |
Why?
|
| Statistics as Topic | 1 | 2014 | 103 | 0.110 |
Why?
|
| Animals | 2 | 2013 | 3503 | 0.110 |
Why?
|
| Axons | 1 | 2013 | 28 | 0.100 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2016 | 221 | 0.100 |
Why?
|
| Oxygen | 1 | 2012 | 63 | 0.100 |
Why?
|
| Visual Cortex | 1 | 2012 | 5 | 0.100 |
Why?
|
| Auditory Cortex | 1 | 2012 | 3 | 0.100 |
Why?
|
| Language Tests | 2 | 2021 | 32 | 0.090 |
Why?
|
| Photic Stimulation | 3 | 2020 | 23 | 0.090 |
Why?
|
| Reward | 1 | 2011 | 21 | 0.090 |
Why?
|
| Task Performance and Analysis | 1 | 2011 | 46 | 0.090 |
Why?
|
| Social Class | 2 | 2022 | 62 | 0.090 |
Why?
|
| Inositol | 1 | 2011 | 6 | 0.090 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 34 | 0.090 |
Why?
|
| Aspartic Acid | 1 | 2011 | 13 | 0.090 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 4 | 0.090 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 8 | 0.090 |
Why?
|
| Antigen Presentation | 1 | 2010 | 15 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 577 | 0.090 |
Why?
|
| Syndrome | 1 | 2010 | 73 | 0.080 |
Why?
|
| Weight Loss | 2 | 2023 | 122 | 0.080 |
Why?
|
| Pain Measurement | 1 | 2011 | 476 | 0.080 |
Why?
|
| HIV-1 | 1 | 2010 | 205 | 0.070 |
Why?
|
| Medicare | 2 | 2019 | 116 | 0.070 |
Why?
|
| Cues | 2 | 2011 | 38 | 0.070 |
Why?
|
| Neuropathology | 2 | 2019 | 79 | 0.070 |
Why?
|
| Comorbidity | 1 | 2009 | 476 | 0.070 |
Why?
|
| Adaptation, Physiological | 1 | 2007 | 43 | 0.070 |
Why?
|
| Cluster Analysis | 2 | 2011 | 43 | 0.070 |
Why?
|
| Functional Laterality | 1 | 2007 | 61 | 0.070 |
Why?
|
| Lewy Bodies | 2 | 2019 | 185 | 0.070 |
Why?
|
| Reading | 1 | 2006 | 37 | 0.060 |
Why?
|
| Evoked Potentials | 1 | 2004 | 12 | 0.060 |
Why?
|
| Dominance, Cerebral | 1 | 2004 | 16 | 0.050 |
Why?
|
| Limbic System | 1 | 2004 | 7 | 0.050 |
Why?
|
| Disease Progression | 2 | 2021 | 655 | 0.050 |
Why?
|
| Cross-Over Studies | 2 | 2014 | 64 | 0.050 |
Why?
|
| Reproduction | 1 | 2023 | 10 | 0.050 |
Why?
|
| Estrogens | 1 | 2023 | 26 | 0.050 |
Why?
|
| Baltimore | 1 | 2003 | 10 | 0.050 |
Why?
|
| Sample Size | 1 | 2003 | 18 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 39 | 0.050 |
Why?
|
| Age of Onset | 2 | 2013 | 89 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 28 | 0.050 |
Why?
|
| Infarction | 1 | 2023 | 25 | 0.050 |
Why?
|
| Reference Values | 1 | 2003 | 181 | 0.050 |
Why?
|
| Maze Learning | 1 | 2002 | 16 | 0.050 |
Why?
|
| Pregnancy | 1 | 2023 | 327 | 0.050 |
Why?
|
| Boston | 1 | 2022 | 19 | 0.050 |
Why?
|
| Cholinergic Antagonists | 1 | 2022 | 8 | 0.050 |
Why?
|
| Physical Therapy Modalities | 1 | 2022 | 73 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 136 | 0.050 |
Why?
|
| Psychotic Disorders | 1 | 2002 | 33 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 24 | 0.050 |
Why?
|
| Incidental Findings | 1 | 2021 | 12 | 0.050 |
Why?
|
| Probability | 1 | 2021 | 87 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2021 | 55 | 0.040 |
Why?
|
| Caribbean Region | 1 | 2020 | 3 | 0.040 |
Why?
|
| South America | 1 | 2020 | 3 | 0.040 |
Why?
|
| Information Dissemination | 1 | 2021 | 18 | 0.040 |
Why?
|
| Amino Acids | 2 | 2010 | 20 | 0.040 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2020 | 5 | 0.040 |
Why?
|
| Lung | 1 | 2021 | 157 | 0.040 |
Why?
|
| New York | 1 | 2020 | 11 | 0.040 |
Why?
|
| Florida | 1 | 2020 | 17 | 0.040 |
Why?
|
| California | 1 | 2020 | 36 | 0.040 |
Why?
|
| Orientation | 1 | 2020 | 5 | 0.040 |
Why?
|
| Walking | 1 | 2022 | 246 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2019 | 12 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2020 | 55 | 0.040 |
Why?
|
| Cerebral Ventricles | 1 | 2019 | 19 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2019 | 25 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 337 | 0.040 |
Why?
|
| Lewy Body Disease | 1 | 2019 | 93 | 0.040 |
Why?
|
| Amyloid | 1 | 2018 | 54 | 0.040 |
Why?
|
| Amygdala | 1 | 2018 | 41 | 0.040 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 115 | 0.040 |
Why?
|
| Serial Learning | 1 | 2018 | 7 | 0.040 |
Why?
|
| Health Status | 1 | 2019 | 214 | 0.040 |
Why?
|
| Perception | 1 | 2018 | 75 | 0.030 |
Why?
|
| Comoros | 1 | 2017 | 1 | 0.030 |
Why?
|
| Neurofibrillary Tangles | 1 | 2018 | 186 | 0.030 |
Why?
|
| Caloric Restriction | 1 | 2017 | 12 | 0.030 |
Why?
|
| Autopsy | 1 | 2018 | 334 | 0.030 |
Why?
|
| Sphygmomanometers | 1 | 2017 | 2 | 0.030 |
Why?
|
| Massachusetts | 1 | 2017 | 17 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 48 | 0.030 |
Why?
|
| tau Proteins | 1 | 2018 | 225 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 74 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 181 | 0.030 |
Why?
|
| Czech Republic | 1 | 2014 | 1 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2014 | 30 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 449 | 0.030 |
Why?
|
| Thalamus | 1 | 2014 | 15 | 0.030 |
Why?
|
| Corpus Striatum | 1 | 2014 | 65 | 0.030 |
Why?
|
| Semantics | 1 | 2014 | 15 | 0.030 |
Why?
|
| Sensation | 1 | 2012 | 12 | 0.020 |
Why?
|
| HIV Long-Term Survivors | 1 | 2010 | 6 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 14 | 0.020 |
Why?
|
| HIV Antigens | 1 | 2010 | 12 | 0.020 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 10 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2010 | 68 | 0.020 |
Why?
|
| Viral Load | 1 | 2010 | 70 | 0.020 |
Why?
|
| Haplotypes | 1 | 2010 | 55 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 84 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2010 | 80 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2010 | 60 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 263 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 391 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 111 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2009 | 255 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 85 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2011 | 3358 | 0.010 |
Why?
|